CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
After a thorough and comprehensive review of proposals received from suppliers of viral marker testi...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
The CTS Medical Advisory Board recently agreed upon a revision to our standard testing algorithm thi...
As a friendly reminder, airlines often change their routine flights and cargo hours for holidays. We...
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
CTS lab staff recently participated in a Kaizen and determined emailed Daily Shipment Schedules to b...